TIL Therapy: Melanoma, Trials, Risks & Access
Status badge: FDA-approved in advanced melanoma; many non-melanoma uses investigational. FDA approved Amtagvi (lifileucel), a TIL therapy, in February 2024 for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocker and, if the tumor has a BRAF V600 mutation, a BRAF inhibitor with or without a MEK inhibitor.
TIL therapy is a type of personalized cell therapy made from immune cells that are already inside a patient’s tumor. These tumor-infiltrating lymphocytes are collected from tumor tissue, expanded in a lab, and then infused back into the patient after preparative chemotherapy. Today, the only FDA-approved TIL therapy use is in advanced melanoma, while many other solid-tumor uses remain under study in clinical trials.
What TIL Therapy Is
TIL stands for tumor-infiltrating lymphocyte therapy. It uses immune cells that have already found their way into a tumor, which may suggest they can recognize cancer. Doctors remove a tumor sample, specialists isolate and grow these lymphocytes in the lab, and then the expanded cells are infused back after lymphodepleting chemotherapy. In many treatment programs, this is followed by interleukin-2, or IL-2, to help support the infused cells.
TIL therapy is different from CAR-T. CAR-T changes T cells with an engineered receptor designed for a specific target, while TIL therapy uses tumor-reactive lymphocytes taken directly from the tumor itself and expanded outside the body. TIL is mainly a solid-tumor cell-therapy strategy, while FDA-approved CAR-T therapies are currently for blood cancers.
Where It Is Approved Today
TIL therapy is FDA-approved today in advanced melanoma. Specifically, FDA granted accelerated approval to Amtagvi (lifileucel) in February 2024 for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, when relevant, BRAF-targeted therapy. This made it the first FDA-approved cellular therapy for a solid tumor.
That approved use should not be generalized to all solid tumors. Outside advanced melanoma, TIL therapy remains investigational and is generally accessed through clinical trials rather than standard approved care.
Solid-Tumor Settings Under Study
TIL therapy is being studied in a growing range of solid tumors beyond melanoma. Current trial and review literature shows ongoing investigation in settings such as non-small cell lung cancer, head and neck cancers, cervical cancer, ovarian cancer, colorectal cancer, breast cancer, and other advanced malignant solid tumors.
Even with that broad interest, these non-melanoma uses are still under study. Availability, eligibility, and evidence level vary by cancer type, trial design, and center experience, which is why patients usually need a trial-focused review rather than assuming TIL is a standard option.
How TIL Treatment Works
Treatment Process
How TIL Therapy Works
Who May Qualify
Whether TIL therapy may fit depends on several factors. The treatment team usually looks at whether there is enough tumor available for harvest, what prior therapy the patient has already received, performance status, organ function, and whether the patient is fit enough for surgery or tumor collection, conditioning chemotherapy, IL-2 support, and hospitalization.
Eligibility box
A patient may be evaluated based on tumor availability, prior therapy history, performance status, organ function, and ability to complete a complex treatment course at a specialized center. In melanoma, approved use is tied to prior PD-1 therapy and, if relevant, prior BRAF-targeted therapy. In other solid tumors, access is usually through clinical trials with their own entry criteria.
Risks and Recovery
The risks of TIL therapy come not only from the cells themselves but from the full treatment package. Major concerns include chemotherapy toxicity from lymphodepletion, IL-2 toxicity, infection, low blood counts, and the burden of hospitalization and recovery. Because lymphodepleting chemotherapy and IL-2 are central parts of treatment, side effects can be intense and often require inpatient care and close monitoring.
Risks
Gene Therapy Risks
Trial-Access Questions
Patients considering TIL therapy often need a trial-access conversation, especially outside melanoma. Useful questions include whether the cancer type has an approved TIL option or only a trial pathway, whether enough tumor is available for harvest, whether prior treatments meet eligibility rules, how intensive the hospital course may be, and whether another therapy should be considered first while trial evaluation is happening.
Questions to Ask Your Care Team
FAQ
What is TIL therapy?
TIL therapy is a personalized cell therapy made from immune cells taken from a patient’s tumor. Those tumor-infiltrating lymphocytes are expanded in a lab and infused back after conditioning chemotherapy to help fight the cancer.
Is TIL therapy FDA-approved?
Yes, but only in a limited setting right now. FDA approved Amtagvi (lifileucel) for adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody and, if appropriate, BRAF-targeted therapy.
Which cancers are being studied?
Beyond melanoma, TIL therapy is being studied in several solid tumors, including lung, head and neck, cervical, ovarian, colorectal, breast, and other advanced solid-tumor settings. These uses are still investigational.
How is TIL different from CAR-T?
TIL therapy uses naturally occurring lymphocytes taken from the patient’s own tumor and expanded in the lab. CAR-T uses T cells that are genetically engineered to recognize a chosen target. TIL is currently the approved cell-therapy approach for a solid tumor, while CAR-T is mainly established in blood cancers.
What side effects matter most?
The biggest side effects usually come from the overall treatment course: lymphodepleting chemotherapy, IL-2 support, infection risk, low blood counts, and the need for hospitalization and recovery monitoring.
How do I ask about TIL trials?
Ask whether your cancer type has an approved TIL option or only trial access, whether your tumor can be harvested, whether you meet prior-treatment requirements, and whether your performance status and organ function fit the treatment plan. ClinicalTrials.gov shows ongoing TIL studies across advanced solid tumors.
treatment for each cancer:
Medical Disclaimer & Source References
© BEIJING BIOTECH.
Clinical Sources: NCCN, ASCO, ACS, ESMO, CSCO, CACA, ChiCTR.
Regulatory Status: TIL therapy has an FDA-approved use in melanoma. Other solid-tumor uses may be investigational.